ASKA Pharmaceutical Holdings Co., Ltd.
4886・Prime Market・Pharmaceuticals
Pharmaceuticals Business
Domestic prescription pharmaceuticals business specialized in three fields: internal medicine, obstetrics/gynecology, and urology
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment net sales | ¥58,927 million (FY2026, ending March 2026) | ¥56,655 million (FY2025, ending March 2025) | ↑ |
| Segment profit | ¥7,121 million (FY2026, ending March 2026) | ¥6,349 million (FY2025, ending March 2025) | ↑ |
| Segment assets | ¥49,098 million (as of March 31, 2026) | ¥49,554 million (as of March 31, 2025) | ↓ |
| Depreciation | ¥1,993 million (FY2026, ending March 2026) | ¥1,693 million (FY2025, ending March 2025) | ↑ |
| Share of consolidated net sales | 82.9% (FY2026, ending March 2026) | 88.3% (FY2025, ending March 2025) | ↓ |
Business Details
Centered on ASKA Pharmaceutical Co., Ltd., this segment manufactures and sells prescription pharmaceuticals, focusing on three fields: internal medicine (thyroid, gastrointestinal), obstetrics/gynecology (uterine fibroids, dysmenorrhea), and urology (prostate cancer, etc.). The main customer is Takeda Pharmaceutical Company Limited (¥57,155 million out of Takeda's consolidated net sales of ¥71,127 million in FY2026 (ending March 2026), approximately 80.4%). Despite the impact of drug price revisions, the segment achieved increased revenue and profit through growth in key products, accounting for 82.9% of consolidated net sales as the core segment.
Recent Overview
Increased revenue and profit driven by growth in key products, with segment profit up 12.1% year on year
Net sales of the Pharmaceuticals Business in FY2026 (ending March 2026) were ¥58,927 million (up 4.0% year on year), and segment profit was ¥7,121 million (up 12.1% year on year). Growth was driven by Relumina (¥11,173 million, +6.1%) and Droeti (¥8,312 million, +10.8%) in the obstetrics/gynecology field, and Thyradin (¥8,775 million, +8.2%) and Rifxima (¥7,883 million, +22.1%) in internal medicine. Meanwhile, Candesartan (¥7,884 million, -7.7%) and Leuprorelin (¥3,880 million, -3.1%) declined. The contraceptive LF111 (Drospirenone) received approval in May 2025.
Key Products
Growth Drivers
- Continued growth of key products in the obstetrics/gynecology field (Relumina and Droeti)
- Positive drug price revision effect for Rifxima and expanded adoption
- Stable growth of Thyradin backed by over 90% domestic market share
- Approval and launch of LF111 (a drospirenone single-agent oral contraceptive) in May 2025
- Progress of Phase III trials for AKP-022 (a relugolix combination drug) for uterine fibroids and endometriosis
- Benefits to certain products from the minimum drug price increase in FY2027 (ending March 2027)
- Promotion of high-quality information provision activities through the specialty area system
Risks
- Ongoing price reduction pressure from annual drug price revisions
- Risk of sales concentration in Takeda Pharmaceutical Company Limited (approximately 80.4% of consolidated net sales via the company)
- Competition from generic pharmaceuticals (e.g., Candesartan and other hypertension treatments down 7.7% year on year)
- Downward pressure on profit margins from increased R&D expenses (R&D expenses of ¥7,060 million in FY2026, ending March 2026; projected ¥8,246 million in FY2027, ending March 2027)
- Declining sales trend for some products such as Leuprorelin
- Risk of increased manufacturing costs due to rising raw material costs and domestic price inflation
- Decline in the Pharmaceuticals Business's share of consolidated net sales due to expansion of the Overseas Business segment
Last updated: June 19, 2026